Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Division of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Sigmund-Freud-Strasse 25, Bonn, Germany.
Moritz
M
Stuplich
Dariusch R
DR
Hadizadeh
Klaus
K
Kuchelmeister
Jasmin
J
Scorzin
Christian
C
Filss
Karl-Josef
KJ
Langen
Niklas
N
Schäfer
Frederic
F
Mack
Heinrich
H
Schüller
Matthias
M
Simon
Martin
M
Glas
Torsten
T
Pietsch
Horst
H
Urbach
Ulrich
U
Herrlinger
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003287:Contrast Media; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018450:Disease Progression; D017809:Fatal Outcome; D005260:Female; D005682:Gadolinium; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant; D000077204:Temozolomide; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003287:Contrast Media; D008130:Lomustine; D003606:Dacarbazine; D005682:Gadolinium; D000077204:Temozolomide